TORULIMOGENE LONFERENCEL
UNII PRT7W2L4WZ

Substance Identification & Data

This profile provides standardized clinical and technical data for Torulimogene Lonferencel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) PRT7W2L4WZ.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

PRT7W2L4WZ

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TORULIMOGENE LONFERENCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C203068

National Cancer Institute reference terminology for clinical and research data.

INN ID

12385

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Torulimogene Lonferencel

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Torulimogene Lonferencel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Torulimogene Lonferencel

Common Names & Synonyms

irradiated human embryonic kidney cells (cell line HEK293) transfected with three self-inactivating, non-replicating lentiviral vectors individually expressing (i) codon-optimised Wilms tumour protein 1 (WT1) isoform D, (ii) codon-optimised cluster of differentiation 1d (CD1d), and (iii) a codon-optimised reverse tetracycline-controlled transactivator (rtTA), a fusion protein of the TetR repressor and the herpes simplex virus VP16 transactivation domain. Expression of both CD1d and rtTA is controlled by the cytomegalovirus immediate early (CMV IE) promoter; expression of WT1 is controlled by an inducible Tet responsive promoter (TRE). Each lentivirus vector also contains a packaging signal (Ψ), a Rev-response element (RRE), a central polypurine tract/central termination sequence (cPPT/CTS) and a Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), and are flanked by a 5' long terminal repeat (LTR) and a 3' self-inactivating long terminal repeat (SIN-LTR). Colonies of transfected cells (expression of CD1d) were established as a Master cell bank (MCB). For the drug substance, cells are expanded and then doxycycline added to induce WT1 in the presence of α-galactosylceramide (α-GalCer), which binds to CD1d forming a CD1d/α-GalCer complex on the cell surface. Finally, the cells are subject to X-ray irradiation. The cells express CD1d (>90%) and intracellular WT1 and the ratio of Cd1d to α-GalCer is determined

torulimogene lonferencel [INN]

External Clinical & Regulatory Resources

Previous UNIIPRS2K479R5

Next UNIIPRT84LK3C5